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Single-Molecule Characterization of the Interactions between
Extracellular Chaperones and Toxic α-Synuclein Oligomers
Abstract

The aberrant aggregation of α-synuclein is associated with several human diseases, collectively termed the αsynucleinopathies, which includes Parkinson's disease. The progression of these diseases is, in part, mediated
by extracellular α-synuclein oligomers that may exert effects through several mechanisms, including prion-like
transfer, direct cytotoxicity, and pro-inflammatory actions. In this study, we show that two abundant
extracellular chaperones, clusterin and α2-macroglobulin, directly bind to exposed hydrophobic regions on
the surface of α-synuclein oligomers. Using single-molecule fluorescence techniques, we found that clusterin,
unlike α2-macroglobulin, exhibits differential binding to α-synuclein oligomers that may be related to
structural differences between two previously described forms of αS oligomers. The binding of both
chaperones reduces the ability of the oligomers to permeabilize lipid membranes and prevents an oligomerinduced increase in ROS production in cultured neuronal cells. Taken together, these data suggest a
neuroprotective role for extracellular chaperones in suppressing the toxicity associated with α-synuclein
oligomers. Whiten et al. report that the extracellular chaperones clusterin and α2-macroglobulin bind directly
to regions of exposed hydrophobicity on the surface of α-synuclein oligomers. This binding significantly
reduces the ability of the oligomers to permeabilize lipid membranes and stimulate the production of reactive
oxygen species in a neuronal cell line.
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SUMMARY

The aberrant aggregation of a-synuclein is associated with several human diseases, collectively
termed the a-synucleinopathies, which includes Parkinson’s disease. The progression of these diseases
is, in part, mediated by extracellular a-synuclein oligomers that may exert effects through several mechanisms, including prion-like transfer, direct cytotoxicity, and pro-inflammatory actions. In this study,
we show that two abundant extracellular chaperones, clusterin and a2-macroglobulin, directly bind
to exposed hydrophobic regions on the surface of
a-synuclein oligomers. Using single-molecule fluorescence techniques, we found that clusterin, unlike
a2-macroglobulin, exhibits differential binding to
a-synuclein oligomers that may be related to structural differences between two previously described
forms of aS oligomers. The binding of both chaperones reduces the ability of the oligomers to permeabilize lipid membranes and prevents an oligomerinduced increase in ROS production in cultured
neuronal cells. Taken together, these data suggest
a neuroprotective role for extracellular chaperones
in suppressing the toxicity associated with a-synuclein oligomers.
INTRODUCTION
The a-synucleinopathies are a group of progressive and, ultimately, fatal neurodegenerative disorders, including Parkinson’s
disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). The pathological hallmark of these disorders
is the selective loss of neurons and the aberrant accumulation of

a-synuclein (aS) within protein inclusions in neuronal or glial cells
(Chiti and Dobson, 2017). How the aggregation of aS causes
disease is still unclear; however, a body of data implicate the
direct cytotoxicity of aS oligomers (Chen et al., 2015; Chiti and
Dobson, 2017; Ingelsson, 2016; Winner et al., 2011). During
the aggregation process, aS oligomers undergo a structural conversion from a relatively unstable species to more stable and
compact oligomers that have increased cytotoxicity and resistance to proteinase-K degradation compared to the preceding
oligomers (Cremades et al., 2012; Horrocks et al., 2015; Iljina
et al., 2016). This conversion occurs before the oligomers are
incorporated into fibrillar structures and is a critical step in the
aggregation pathway of aS.
aS can account for up to 1% of all cytosolic proteins in neurons, but it is also present in extracellular fluids, including cerebrospinal fluid (CSF) and blood plasma (El-Agnaf et al., 2003).
Recent evidence suggests that this extracellular aS significantly
contributes to the onset and spreading of disease within the
affected brain (Lee et al., 2014). Indeed, as with a growing number of neurodegenerative diseases, it appears that the local
spread of pathology may be due to a prion-like propagation pro et al., 2014; Chiti and Dobson, 2017; Emmanouilidou
cess (Aulic
and Vekrellis, 2016; Marques and Outeiro, 2012). Direct neurotoxicity of extracellular aS has also been observed, which could
be caused by the unregulated insertion of aS aggregates into cell
membranes and/or neuroinflammatory responses such as microglia activation and generation of intracellular reactive oxygen
species (ROS) (Cremades et al., 2012; Fusco et al., 2017; Reynolds et al., 2011; Zhang et al., 2005).
Extracellular chaperones (ECs) are a small class of proteins
that act efficiently to enhance the clearance of misfolded proteins from extracellular body fluids. Clusterin (CLU) was the first
mammalian EC discovered (Wilson and Easterbrook-Smith,
2000) and has been shown to inhibit the aggregation of a very
broad range of proteins, including aS (Yerbury et al., 2007).
Thus, since both CLU and aggregates of aS can be present
together outside cells, a direct in vivo interaction between the
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two proteins is feasible and likely. Similarly, another well characterized EC, a2-macroglobulin (a2M) (Wyatt et al., 2014), may also
interact with aS. A polymorphism in the a2M gene has been
linked with PD, although this link cannot be established for all
€ger et al., 2000; Nicoletti et al., 2002; Tang
populations (Kru
et al., 2002).
In addition to a possible extracellular interaction, CLU and aS
may interact within the cellular environment. Under conditions
of endoplasmic reticulum (ER) stress, the secretion of CLU to
the extracellular environment is inhibited, and the protein is retrotranslocated from the ER and/or Golgi to the cytosol (Nizard
et al., 2007; Zhang et al., 2014). We have recently shown that
this process is sufficient to protect cultured neuronal cells
and Drosophila melanogaster from proteotoxicity associated
with the aggregation of the amyotrophic lateral sclerosis
(ALS)-linked protein TDP-43 (Gregory et al., 2017). ER stress
has been linked to both ALS and PD pathologies; moreover,
the overexpression of mutational variants of aS is sufficient to
induce ER stress (Gallegos et al., 2015). These observations
suggest that a cytosolic interaction between aggregated aS
and CLU is also possible. Indeed, CLU has been found colocalized with intracellular aS in patients with a variety of diseases, including cortical Lewy bodies in DLB, brain stem
Lewy bodies in PD and DLB, and glial cytosolic inclusions in
MSA (Sasaki et al., 2002).
Despite the potentially critical importance of the binding between ECs and aS oligomers, our understanding of the nature
of the interaction is limited. Previous work has shown that both
CLU and a2M bind to misfolded proteins to inhibit their aggregation (Wyatt et al., 2013). However, very limited information is
available regarding whether specific sizes or structures of oligomers are bound preferentially or on the stoichiometries of binding of chaperone to misfolded client proteins. CLU is known to
interact with oligomers of the 40-amino-acid isoform of amyloid-b (Ab), ranging from dimers up to 50mers (Narayan et al.,
2011). CLU also forms stable high-molecular-weight complexes
with amorphous aggregates of proteins with a mass ratio of 1:2
(CLU:client) (Wyatt et al., 2009); however, the stoichiometry of
complexes formed between either CLU or a2M and amyloidforming proteins is not known.
In this report, we used a single-molecule fluorescence technique, termed two-color coincidence detection (TCCD) (Orte
et al., 2008a), to show that both CLU and a2M interact directly
with aS oligomers. TCCD allows the properties of two individual
proteins, each labeled with one of two spectrally distinct fluorophores, to be studied with high sensitivity (Horrocks et al., 2015).
This approach allows the detection of individual species by
avoiding measurements of ensemble averages and has been
used previously to study the kinetics of aS aggregation (Cremades et al., 2012; Horrocks et al., 2015). In the present study,
we demonstrate that the interactions between the chaperones
and aS oligomers are inhibited by 4,40 -dianilino-1,10 -binaphthyl-5,50 -disulfonic acid (bisANS), suggesting that the binding involves exposed hydrophobic groups on the surface of the
oligomers. Additionally, we show that the chaperones specifically inhibit both an aS-induced increase in lipid membrane
permeability and the aS-induced induction of ROS production
in neuronal cells.

RESULTS
We first performed TCCD measurements to explore the interaction of the ECs with aS during the aggregation process. To
achieve this, we made use of the A90C mutational variant
aS, which allows the conjugation of a fluorophore through a
single thiol group; previous studies have shown that the conjugation does not significantly change the behavior of the protein
from that of wild-type aS (Cremades et al., 2012). aSA90CAF488 (70 mM) was incubated under aggregation-inducing
conditions in the presence of CLU-AF647 (0.7 mM). We took aliquots from the aggregation reaction and monitored, via TCCD,
the stoichiometry of any CLU:aS complexes formed. The number of monomers in an oligomer is estimated based on the total
fluorescence intensity of the oligomer compared to that of the
monomer. Since this is not a direct measurement of the oligomer size, and is approximate, we refer to this as the apparent
size. Wherever the term ‘‘monomer’’ is used regarding CLU
and a2M, we are referring to the physiological heterodimer
and tetramer, respectively. Under these conditions, both
CLU and a2M were found to greatly inhibit the aggregation of
wild-type aS (Figure S1). Previous fluorescence lifetime experiments have shown that AF488 conjugated to aS is not
quenched during the oligomerzation of the protein (Cremades
et al., 2012). Additionally, since CLU-AF647 did not show any
evidence of quenching when bound to unlabeled aS fibrils (Figure S1), we assumed that fluorescence quenching is not a significant factor, particularly when bound to the small oligomers.
We were interested to see to which species CLU was bound,
and so we searched for coincidence events between the two
different fluorophores. After 6 hr of aggregation, we observed
coincident events showing that CLU was predominantly bound
to small oligomers (approximately tetramers) with an equimolar
stoichiometry to aS. For larger oligomers, CLU was found to
bind to aS at substoichiometric ratios, with an average CLU/
aS ratio of 0.1 calculated for the largest oligomers detected
(Figures 1A and 1C). As expected, after 48 hr of aggregation,
a larger number of aS oligomers were detected than after
6 hr (Figures 1B and 1D; additional time points are shown in
Figure S2). At this later time point, as at 6 hr, a population of
larger aS oligomers with a low CLU/aS ratio (approximately
0.06) was detected (Figures 1B and 1D). In addition, a population of ‘‘CLU-rich’’ oligomers were also detected (Figure 1B).
These CLU-rich oligomers had an average CLU/aS ratio of
0.8 and generally contained less than 15 aS monomers. Overall, these data show that CLU binds to a wide range of aS
species, from at least dimers to oligomers containing 30 aS
molecules.
We next studied the formation of a2M-aS complexes in a
manner similar to that used for CLU, as described earlier.
aSA90C-AF488 (70 mM) and a2M-AF647 (0.7 mM) were co-incubated under conditions that facilitated aggregation, and the resulting oligomers were examined using TCCD at various time
points. Similarly to CLU, a2M significantly inhibited the aggregation of aS under these conditions (Figure S1), and again, after 6 hr
of incubation, the resulting small aS oligomers showed a broad
distribution centered around an equimolar stoichiometry with
a2M (Figures 2A and 2C). The ratio tended to decrease as
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Figure 1. The Ratio of CLU:aS Decreases in
Larger Oligomers
aSA90C-AF488 (70 mM) and CLU-AF647 (0.7 mM)
were co-incubated in PBS (pH 7.4) at 37 C, with
shaking at 200 rpm. The formation of aS-CLU
complexes was quantified by single-molecule
TCCD.
(A and B) Contour plots of the apparent number of
aS monomers constituting an oligomer as a function of the ZCLU/aS value for samples taken from the
aggregation reaction after 6 hr (A) and 48 hr (B),
respectively. ZCLU/aS represents the logarithm of
the apparent ratio of CLU to aS in each oligomer.
The data shown are representative of three separate experiments. The numbers in the inserts
indicate the number of complexes represented in
the plot.
(C and D) Frequency histograms of the number of
oligomers at different ZCLU/aS values (for the data
shown in A and B, respectively). The dotted lines
each indicate a specific CLU: aSA90C stoichiometry
(as shown on the upper x axis). The data are
representative of three independent experiments.

increasing numbers of aS monomers were present in the oligomer. The largest oligomers detected (consisting of 30 aS molecules) had an approximate a2M/aS ratio of 0.03. After aSA90CAF488 had been incubated with a2M-AF647 for 48 hr, oligomers
were more abundant and tended to contain more a2M than similarly sized oligomers after 6 hr of incubation (Figures 2B and 2D;
additional time points are shown in Figure S2). Small oligomers
detected in the aggregation reaction after 48 hr still had an
approximate equimolar ratio of a2M:aS. However, in the largest
oligomers detected at 48 hr (containing 30 aS monomers),
the a2M/aS ratio was around 0.1, approximately three times
greater than at the 6-hr time point. In order to further compare
the differences in binding stoichiometry at various times during
the aggregation reaction, the average numbers of apparent
a2M and aS monomers in different oligomers were plotted (Figures 2E and 2F). This reveals that (1) at all time points, there was a
linear dependence of the a2M:aS ratio on oligomer size (Figure 2E), and (2) the a2M:aS ratio increased linearly over time
for oligomers of all sizes (Figure 2F).
To further investigate the binding of the ECs to the oligomers,
we examined whether this binding was a result of hydrophobic
interactions by exploiting the effects of the presence of bisANS,
a well-established probe of solvent-exposed hydrophobicity
(Bothra et al., 1998; Poon et al., 2002; Sheluho and Ackerman,
2001). We first incubated wild-type aS for 9 hr under aggregating
conditions and examined the species formed at this time point by
super-resolution microscopy using Nile red; we found that they
matched the characteristics observed previously for oligomers
3494 Cell Reports 23, 3492–3500, June 19, 2018

formed under these conditions (i.e.,
approximately spherical and <200 nm
in diameter; Figure S3). The mixture of
monomeric and oligomeric aS was adsorbed to a microplate and next blocked
with BSA and treated with a range of
concentrations of bisANS to block any
exposed hydrophobic regions. Following subsequent incubation
with either CLU or a2M, the extent of chaperone binding was assessed by an ELISA. The bisANS dose-dependently reduced the
binding of both CLU and a2M to the aS oligomers (Figures 3A and
3B), suggesting that the hydrophobic regions exposed on the
surface of the oligomers mediates the binding. Neither of the
chaperones was found to bind to the BSA blocker or to monomeric aS (Figure S3).
Having shown that the chaperones bind to exposed hydrophobic regions present on aS oligomers, we hypothesized
that this binding could act to reduce the cytotoxicity of the
oligomers. For this purpose, we first used a methodology that
enables the quantification of aggregate-induced toxicity by
measuring their effects on the permeability of a lipid bilayer
(Flagmeier et al., 2017). In this assay, the Ca2+-sensitive dye
Cal-520 is incorporated into surface-tethered vesicles, and
Ca2+ present in solution can enter the vesicles when the lipid
membrane is permeabilized (by, for example, a protein oligomer). The resulting increase in fluorescence intensity can be
quantified by total internal reflection fluorescence (TIRF) microscopy and used to determine the extent of membrane permeability. In contrast to a non-EC control protein (BSA), incubation
of aS oligomers with both CLU and a2M significantly reduced
the ability of the oligomers to permeabilize the membranes
(96 ± 4% and 69 ± 7% protection at a 1:10 substoichiometric
ratio of chaperone to monomer, respectively; Figures 3C and
3D). BSA did not reduce the Ca2+ influx even when present
at an equimolar ratio of BSA:aS (Figure S3). The effect of the

Figure 2. Time-Dependent Changes in the
Association of a2M with aS Oligomers
aSA90C-AF488 (70 mM) and a2M-AF647 (0.7 mM)
were co-incubated in PBS (pH 7.4) at 37 C, with
shaking at 200 rpm. The formation of aS-a2M
complexes was quantified by single-molecule
TCCD.
(A and B) Contour plots of the apparent number of
aS monomers constituting a given oligomer as a
function of the Za2M/aS value for samples taken
from the aggregation reaction after 6 hr (A) and 48
hr (B). Za2M/aS represents the logarithm of the
apparent ratio of a2M to aS in each oligomer. The
numbers in the inserts indicate the number of
complexes represented in the plot.
(C and D) Frequency histograms of the number of
oligomers at different Za2M/aS values (for the data
shown in A and B, respectively). The dotted lines
each indicate a specific a2M:aSA90C stoichiometry
(as shown on the upper x axis). Data are representative of three independent experiments.
(E) aSA90C-AF488 (70 mM) and a2M-AF647 (0.7 mM)
were co-incubated in PBS at 37 C, with shaking at
200 rpm, for the indicated time. For each time
point, the average numbers of apparent monomers
of a2M and aS per oligomer were calculated. The
data were fitted to linear regressions.
(F) The gradients of each linear regression for each
time point shown in (A). A time-dependent linear
increase in the amount of a2M found bound to aS
can be observed. Data shown are means ± SEM
(n = 3).

chaperones was dose dependent, with both chaperones
providing >95% protection at a concentration equimolar to
that of monomeric aS. Additionally, both CLU and a2M reduced
the aS-induced permeabilization when aS was aggregated in
the presence of the chaperone in a 1:100 substoichiometric ratio of chaperone to aS monomer (Figure S3).
To determine whether this effect was sufficient to alter the
cellular response to aS oligomers, we measured the effect of
both ECs on the cellular production of ROS (Cremades et al.,
2012). Intracellular ROS has previously been shown to activate
apoptosis in neurons (Jenner, 2003) and is typically one of the
first aberrant cellular responses induced by exposure to toxic
protein oligomers (Canevari et al., 2004; Zampagni et al.,
2011). The oxidation of dihydroethidium (DHE) to ethidium was
used to measure the rate of ROS production immediately after
the addition of aS oligomers to Neuro-2a cells, in the presence
or absence of the ECs. The addition of pre-formed oligomers

alone, or of oligomers preincubated with
BSA, resulted in an approximately 2.5fold increase in the rate of ROS production. Preincubation of the oligomers with
CLU or a2M ameliorated their ability to
induce ROS formation in cells (Figures
3E and 3F). As neither chaperone alone
had any effect on the rate of ROS production, the protective effect is not the result
of the chaperones inhibiting the ability of
the cells to produce ROS but rather indicates a protective effect
conferred by the ECs binding to the oligomers.
DISCUSSION
In the present study, we investigated the direct interaction of
ECs with aS under conditions where aggregation occurs. We
first used TCCD to examine the stoichiometry of the EC/aS
complexes. Using this approach, we have shown that the nature of the binding between the chaperones and aS oligomers
is specific for each chaperone and, in the case of CLU, appears
to depend on subtle differences in the oligomeric structures.
In aliquots taken from aggregation reactions after 6 hr, the
stoichiometry of the complexes formed between each EC and
aS were similar. Both chaperones tended to bind small oligomers (<5 aS monomers) in an approximate equimolar ratio.
Oligomers containing >5 aS monomers were observed to be
Cell Reports 23, 3492–3500, June 19, 2018 3495

Figure 3. Hydrophobic Shielding Reduces the Ability of aS Oligomers to Induce Membrane Disruption and ROS Production

(A and B) BisANS inhibits the binding of CLU (A) and a2M (B) to aS oligomers. The chaperones (present at 10 mg , mL1) were incubated in an ELISA plate precoated with aggregated aS, and the amount of bound chaperone was then measured by ELISA. Neither chaperone bound to monomeric aS or the BSA blocker
(Figure S3). Data shown are means ± SD of three independent experiments.
(C) aS oligomers were pre-incubated with CLU, a2M, or BSA and then added to surface-tethered lipid vesicles filled with the Ca2+-sensitive fluorophore Cal-520.
The extent of membrane permeabilization was quantified as a percentage of maximum fluorescence produced after incubation with the Ca2+ ionophore ionomycin. Example images of vesicles after the addition of the indicated sample are shown. Scale bar (bottom right), 2 mm.
(D) Quantification of the data shown in (C). a2M or CLU (0.05–50 nM) was incubated with aggregated aS. The extent of membrane permeabilization decreased
with increasing chaperone concentration. Data shown are means ± SD of 9 fields of view (at least 800 vesicles) and are representative of two independent
experiments.
(E) Aggregated aS preincubated with CLU, a2M, or BSA (each present at a 1:10 substoichiometric ratio) was added to Neuro-2a (N2a) cells. The rate of ROS
production before and after the sample addition was quantified by measuring the oxidation of DHE to ethidium by epifluorescence microscopy. The change in the
rate of ROS generation due to the addition of a sample was calculated by subtracting the gradient of the pre-addition line from the gradient of the post-addition
line. Example rates of ROS production in a single cell under the indicated conditions are shown.
(F) Quantification of the data shown in (E). The change in the rate of ROS production produced by each sample relative to the buffer-only sample is
indicated. The values are means ± SD of approximately 50 cells across three replicate treatments. **p < 0.01, analyzed by one-way ANOVA with a
Bonferroni post-test.

associated with proportionally less chaperone, suggesting that
the number of chaperone-accessible binding sites on the aS
oligomer surface does not increase linearly with the number
of aS monomers in an oligomer. These data also indicate
that, on average, slightly fewer a2M molecules are associated
with the oligomers of all sizes when compared with CLU. This
is likely to be the result of the significant difference in size between the two chaperones: a2M is much larger than CLU
(approximately 720 kDa for the a2M tetramer and 80 kDa for
the CLU heterodimer). CLU is known to exist in solution as a
polydisperse mixture of oligomers of the heterodimer (Hochgrebe et al., 2000; Poon et al., 2002). It is not known whether
these species exhibit variable chaperone activity; however,
even a CLU tetramer is approximately half the size of a2M.
3496 Cell Reports 23, 3492–3500, June 19, 2018

As a result, the binding of a2M to aS is likely to be sterically
limited by previously bound chaperones to a greater extent
than for CLU. This could potentially help explain the observation that dimeric a2M is a more efficient chaperone than the
native tetramer (Wyatt et al., 2014). The biological function of
CLU oligomers is not known, although it has been suggested
that they act as reservoirs of a more chaperone-active CLU
heterodimer that is released when required (Poon et al.,
2002). Unfortunately, the role of these oligomers is difficult to
investigate experimentally using single-molecule techniques
due to the rapid dissociation of the oligomers upon dilution.
Interestingly, compared to the complexes observed after 6 hr
of incubation, a distinct population of CLU/aS complexes
emerged at later time points that were relatively large (up to

15 aS monomers) and CLU rich (CLU/aS ratio = 0.8). One
possible explanation for the appearance of this population may
be a time-dependent association of additional aS monomers
with already formed CLU/aS complexes; however, the clear
delineation between this population and those observed at 6 hr
suggests that this is not the case. It was recently shown that
aS oligomers exhibit a broad distribution of structure-dependent
surface hydrophobicity (Bongiovanni et al., 2016). The data presented here indicate that the binding of CLU to the oligomers is
mediated by hydrophobicity, suggesting that the ability of CLU to
bind to the oligomers is dependent on some aspect of the oligomer structure. Furthermore, the observed time dependence
of the differential binding of CLU to aS oligomers cannot be explained by the differential binding of CLU monomers and oligomers, which are both present at the start of the experiment
before dilution for single-molecule measurements. This can,
however, be explained by CLU binding to aS oligomers of
different structures.
Both a2M and CLU have previously been shown to reduce
the toxic effects of Ab oligomers (Fabrizi et al., 2001; Narayan
et al., 2014) and reduce the toxicity of CSF from Alzheimer’s
disease patients and healthy controls (Drews et al., 2017; Yerbury and Wilson, 2010). This is believed to be a result of the
endocytic clearance of the oligomer from the extracellular
space through the formation of oligomer-chaperone complexes
such as those directly observed in this report. This process is
thought to be one of the central systems acting to maintain
extracellular proteostasis (Wyatt et al., 2013). Additionally, the
work presented here indicates that the binding of ECs to
oligomers directly inhibits the latter from aberrantly interacting
with lipid membranes. Similarly to other client proteins (Poon
et al., 2002), the association between ECs and aS oligomers
appears to be mediated by regions of exposed hydrophobicity,
evidenced by the inhibition of binding by the hydrophobic
probe bisANS. Thus, by interacting with the oligomers, chaperones appear to shield the surface hydrophobicity present on
the oligomers. Although the precise mechanism by which aS
oligomers confer cytotoxicity is unknown, direct membrane
disruption appears to be one of the contributing factors
(Poon et al., 2002). Given that hydrophobicity contributes to
the interaction between aS and lipid membranes (Pfefferkorn
et al., 2012; van Rooijen et al., 2009), it is not surprising that
the chaperones inhibited the permeabilization of lipid vesicles
caused by aS oligomers. This provides a feasible mechanistic
explanation for the observation that the chaperones prevent
an increase in ROS production elicited by the oligomers.
Overall, despite evidence that the binding of both a2M and
CLU to aS oligomers is mediated by surface-exposed regions
of hydrophobicity on the oligomers, the binding of each chaperone shows unique characteristics. The data suggest that the
interaction between the chaperones and aS oligomers appears
to depend on both the identity of the chaperone and the structural properties of the oligomer. When considered alongside
the chaperone-mediated reduction in aS-induced membrane
permeability and ROS production, these data provide evidence
to support a neuroprotective role for ECs in the a-synucleinopathies and suggest a mechanism by which these chaperones may
operate within other disease contexts.

EXPERIMENTAL PROCEDURES
Protein Purification and Labeling
aS (wild-type and A90C; aSA90C), CLU, and a2M were purified as described
previously (see Cremades et al., 2012; French et al., 2008; and Poon et al.,
2002, respectively). aSA90C was labeled with either Alexa Fluor 488 (AF488)
C5 maleimide or Alexa Fluor (AF647) C2 maleimide (Invitrogen). The aS was first
incubated for 15 min with 10 mM DTT at room temperature (RT) to ensure
reduction of the engineered cysteine residue. The reduced aSA90C was
concentrated to approximately 400 mM using a Vivaspin 500 (10,000 MWCO)
and buffer exchanged through a PD-10 column (GE Healthcare Life Sciences)
into degassed PBS. The protein was then added to a 1.5-fold molar excess of
the functionalized fluorophores, and the tube was flushed with nitrogen to prevent oxidation of the cysteines. The protein was incubated at 4 C overnight,
with shaking followed by purification from unreacted fluorophore using a
PD-10 column equilibrated in PBS (pH 7.4). The fluorescent labeling of
aSA90C has previously been shown to have minimal influence on the aggregation of the protein (Cremades et al., 2012; Horrocks et al., 2015). Similarly, CLU
and a2M (Sigma Aldrich) were individually labeled with N-hydroxysuccinimidyl
ester forms of either AF488 or AF647 (Invitrogen). To achieve this, the proteins
(each at approximately 2 mg , mL1) were incubated with a 10-fold molar
excess of the functionalized fluorophore for 1 hr at RT or overnight at 4 C. Unconjugated dye was removed by buffer exchange into PBS (or PBS with 0.01%
azide in the case of a2M) using a PD-10 column. The final protein concentration
and labeling efficiency were determined according to the manufacturer’s
instructions.
Aggregation of aS
Any pre-aggregated material present in the monomer stock was first removed
from the monomer population by ultra-centrifugation at 90,000 rpm for 1 hr at
4 C. Then, aS was aggregated in the presence or absence of the ECs. When
present, the chaperone was used at a molar ratio to aS of 1:100. All aggregations were performed using 70 mM aS in PBS (pH 7.4), with shaking at 200 rpm,
37 C, in an Innova43 Incubator Shaker Series (New Brunswick Scientific). Protein LoBind tubes (Eppendorf) were used to minimize protein adsorption; time
point samples were flash frozen in liquid nitrogen for storage before use.
Microfluidics
Single-channel microfluidic devices were used to increase the rate of data
acquisition through sample flow and remove the bias for preferentially
measuring smaller species that occurs as a result of diffusion. These devices
were made of polydimethylsiloxane (PDMS), patterned using a silicon wafer,
and bonded to borosilicate glass cover slides by exposure to oxygen plasma.
The construction and use of these devices for examining aS aggregation has
been described previously (Horrocks et al., 2015).
Single-Molecule TCCD
TCCD measurements were performed with fluorescent proteins present at
50 pM. Dilutions, in freshly filtered (0.02 mm) PBS, were performed immediately
before analysis. TCCD measurements were made using a custom-built
confocal microscope. Briefly, the intensities of a 488 nm laser (Spectra Physics
Cyan, CDRH) and a 633 nm laser (Melles Griot, 25-LHP-151 helium neon
[HeNe]) were first attenuated using neutral density filters. The beams were
expanded and collimated by passage through a spatial filter (488 nm laser) or
telescopic lenses (633 nm laser) before being made concentric with a dichroic
mirror (505DRLP Omega Filters). The beams were then directed into the back
port of an inverted microscope (Nikon Eclipse TE2000-U) and focused 10 mm
into the sample by a Fluor 100X, 1.30 NA, oil-immersion objective (Nikon).
The emitted fluorescence was collected by the same objective and passed
through a 50 mm pinhole (Melles Griot) before being separated into two channels by a further dichroic mirror (585DRLP, Omega Filters). Emission in each
channel was passed through long-pass and band-pass filters (535AF45 and
510ALP Omega Filters for the blue-green channel and 696AF55 and 565ALP
Omega Filters for the red channel) and focused on avalanche photodiodes
(Perkin-Elmer Optoelectronics, SPCM-14) for quantification.
The apparent size of an oligomer measured by confocal microscopy was
calculated by first determining the fluorescence intensity of the monomer.
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This was typically given by the average intensity of non-coincident events
before the sample was incubated under conditions to promote aggregation.
The number of monomers in each coincident burst was then characterized as:
NMonomers =

ID
IA
+
IMD IMA

where ID and IA are the intensities of the coincident burst in the donor and
acceptor channels, respectively; and IMA and IMD are the mean monomer intensities in the donor and acceptor channels, respectively (Orte et al., 2008a). In a
similar fashion, the natural logarithm of the apparent ratio of chaperone to client
in each oligomer (Z) was calculated according to the following equation:

0
Z = ln@

Ichaperone
Imchaperone


Iclient
Imclient

1

A

where I refers to the intensity of a peak above the threshold from fluorophores
conjugated to the chaperone or client protein, and Im refers to the intensity of
the monomer. These Z values are used to display the ratio of chaperone to
client, so that the scale is visually symmetrical around a 1:1 stoichiometry
(Z = 0). It should be noted that, in these experiments, the apparent monomer
intensity determined from any given dataset is dependent upon the value
used to threshold those data. However, since the threshold was determined
automatically, as described previously (Clarke et al., 2007; Orte et al.,
2008b), the error in the calculated number of monomers labeled with each
fluorophore is the same when comparing the two labeled species. Thus, all
references to the number of monomers constituting an oligomer refers
to apparent monomers, and although the given values scale correctly with
each other, they may differ from the true value.
TIRF Microscopy
Borosilicate glass cover slides (24 3 50 mm, thickness number 1; VWR International) for use in TIRF microscopy were cleaned by exposure to oxygen
plasma for 30 min (FEMTO plasma system, Diener Electronic). Frame-Seal incubation chambers (Bio-Rad) were attached to the surface of the slides to
create wells, which were then coated in aspartic acid (1 mg/mL; Sigma Aldrich)
for 15 min. The aspartic acid was removed, and the slide was rinsed with PBS
before use. Samples were analyzed at approximately 3 mM monomer equivalents—a concentration that allowed individual aggregates to be resolvable on
the surface of the slide. Either 5 mM thioflavin T or 5 nM Nile red was added to
the sample before imaging to visualize aS aggregates (Bongiovanni et al.,
2016). Measurements were performed on a custom-built inverted optical microscope. The intensities of 405 nm, 532 nm, and 641 nm lasers were attenuated using neutral density filters, after which the beams were circularly polarized using quarter-wave plates specific to each wavelength. The beams were
then expanded and collimated using Galilean beam expanders and made
concentric using dichroic mirrors before being passed through the back aperture of an inverted microscope and focused using an oil immersion TIRF objective (APON60XO TIRF, Olympus). Fluorescence emission was separated from
excitation light using dichroic mirrors (Di02-R532 and Di01-R405/455/561/635
for 532 nm and 405/641 nm excitation, respectively; Semrock) and passed
through appropriate filters (BLP01-488R-25, LP02-568RS-25, and BLP01635R-25 for 405 nm, 532 nm, and 641 nm excitation, respectively; Semrock).
The fluorescence was then expanded and focused on an electron-multiplying
charge-coupled device (Evolve 512, Photometrics) for imaging.
Super-resolution images were reconstructed using the Drift Calculator
and Peak Fit package (GDSC SMLM, University of Sussex) in ImageJ using
gain = 37.7 analog to digital units (ADU) per photon, minimum photons >30,
and precision <30 nm. Cluster analysis was performed to remove random localizations using DBSCAN (sklearn v0.18.1, Python 2.7); minimum points
threshold = 10, and epsilon = 3.
ELISA
aS was aggregated for 9 hr as described earlier, centrifuged at 13,000 3 g for
10 min to remove any large aggregates, and then diluted to 2.5 mM. The protein
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was then adsorbed to a high-binding 96-well microplate (Corning) for 2 hr at RT
with gentle shaking. After the incubation, the plate was rinsed with PBS and
blocked with 150 mM BSA as described earlier. Some wells were then incubated with bisANS (Sigma) in a concentration range of 0–100 mM to block solvent-exposed hydrophobic regions (Poon et al., 2002). Following this, the wells
were incubated with CLU or a2M for 1 hr at RT (each at 10 mg , mL1 diluted
into the BSA blocking solution). The wells were then rinsed five times with
PBS before the amount of bound chaperone was quantified using horseradish
peroxidase (HRP)/chromogen detection of appropriate antibodies according
to the manufacturer’s instructions (antibodies and reagents from CLU and
a2M ELISA kits, ab174447 and ab108883, respectively; Abcam).
Single Vesicle Assay
A quantitative vesicle assay was used to measure the ability of aS oligomers to
permeabilize membranes as described previously (Flagmeier et al., 2017). aS
was aggregated as described earlier, and aliquots were removed and diluted
so that the final concentration of aS added to the vesicles was 50 nM. The
diluted samples were preincubated for 5 min at RT in the presence or absence
of a2M, BSA, or CLU (concentrations are indicated in the legend for Figure 3)
before being added to the solution above POPC lipid vesicles containing Cal520 (100 mM; Stratech Scientific) tethered to the surface using biotin/neutravidin linkage. A change in the fluorescence as a result of Ca2+ (present at 1.3 mM
in L-15 buffer; Thermo Fisher Scientific) entering the vesicles was quantified by
means of TIRF microscopy using a 488 nm laser for excitation (Toptica Photonics) and emission filters BLP01-488R-25 and FF01-520/44-25 (Semrock).
The fluorescence intensity of each vesicle was then normalized to the
maximum possible fluorescence intensity of the vesicle measured following
incubation with ionomycin (1.4 mM; Sigma). For each sample, the acquisition
of 9 fields of view (3 3 3 grid) was automated to prevent user bias.
DHE Assay
DHE was used to measure the intracellular rate of ROS production in Neuro-2a
cells, using a method similar to that previously described (Cremades et al.,
2012). The cells were cultured in DMEM/Ham’s Nutrient Mixture F-12 (Thermo
Fisher Scientific) supplemented with 10% (v/v) fetal bovine serum (Bovagen
Biologicals) and incubated in a Heracell 150i CO2 incubator (Thermo Fisher
Scientific) under 5% (v/v) CO2 at 37 C. Cells to be analyzed were seeded in
24-well plates and left to grow to approximately 50% confluency. The cells
were rinsed with PBS before DHE (2 mM in PBS) was added. An epifluorescence microscope was used to quantify both the oxidized (ethidium: excitation, 405–435 nm; emission, 440–480 nm) and reduced (DHE: excitation,
502–560 nm; emission, 590–630 nm) forms of DHE. Measurements were taken
every 30 s for 15 min before the addition of aggregated aS (30-mM monomer
equivalent) with and without preincubation with BSA, CLU, or a2M (all: 3 mM,
5 min at RT). DHE (2 mM) was present in any sample added to the cells to prevent the dilution of the fluorophore. Measurements were then taken of the
same cells for a further 15 min. The ratio of the mean ethidium intensity to
the mean DHE intensity before and after the addition of the sample was calculated; a linear regression was fitted to the data, and the gradient of the slope
was used to determine the change in the rate of oxidation of DHE within cells.
In each experiment, the first two data points collected after the addition of the
DHE and sample (i.e., the 0-, 0.5-, 15.5-, and 16-min time points) were
excluded from the analysis, as the sample addition briefly disturbed the fluorescence measurement.
SUPPLEMENTAL INFORMATION
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